此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Upadacitinib in Isolated Small Bowel Versus Non-Small Bowel Crohn's Disease

Comparable Efficacy of Upadacitinib in Isolated Small Bowel Versus Non-Small Bowel Crohn's Disease: A Retrospective Cohort Study

Background & Aims: Isolated small bowel Crohn's disease (CD) is defined by involvement of the ileum, jejunum, or extensive small intestinal segments in the absence of colonic disease. This phenotype presents a therapeutic challenge, as biologic agents demonstrate reduced efficacy in this subgroup. Data on the use of upadacitinib specifically for isolated small bowel CD remain limited. This study aimed to evaluate the efficacy of upadacitinib in patients with this phenotype using the International Bowel Ultrasound Segment Activity Score (IBUS-SAS).

Methods: A retrospective cohort study including individuals with active Crohn's disease (CD) who received 12-week induction therapy with upadacitinib (45 mg/day) was conducted. Based on whether the disease involved the small bowel, individuals were categorized into an isolated small bowel CD group and a non-small bowel CD group. The primary endpoint was the change in the International Bowel Ultrasound Segment Activity Score (IBUS-SAS) from baseline to week 12. Secondary endpoints at week 12 included radiographic response (defined as a>25% or>2.0 mm reduction in bowel wall thickness [BWT] from baseline, or a>1.0 mm reduction in BWT from baseline accompanied by a decreased Color Doppler Signal grade), change in clinical activity as measured by the Crohn's Disease Activity Index (CDAI) from baseline, and changes in laboratory parameters (C-reactive protein, erythrocyte sedimentation rate). Statistical analyses included between-group comparisons, within-group comparison and logistic regression to identify predictors of radiographic response.

研究概览

地位

完全的

研究类型

观察性的

注册 (实际的)

3

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Guangzhou
      • Guangdong、Guangzhou、中国、510000
        • The Sixth Affiliated Hospital of Sun Yat-sen University

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

取样方法

非概率样本

研究人群

This retrospective case-control study consecutively enrolled individuals with Crohn's disease who initiated upadacitinib treatment at The Sixth Affiliated Hospital of Sun Yat-sen University between March 2023 and December 2024.

描述

Inclusion Criteria:

  • confirmed diagnosis of Crohn's disease (CD) based on the 2023 Chinese clinical practice guidelines (Guangzhou);
  • initiated upadacitinib treatment (45 mg once daily) and completed at least 12 weeks of follow-up;
  • underwent intestinal ultrasound examinations both before treatment initiation and at week 12

Exclusion Criteria:

  • age <18 years;
  • concomitant use of other CD medications during upadacitinib treatment, including glucocorticoids, mesalazine, immunosuppressants, or biologics;
  • undergoing surgical intervention during the upadacitinib treatment period
  • history of other gastrointestinal diseases (e.g., ulcerative colitis, intestinal tuberculosis);
  • incomplete clinical data.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
干预/治疗
case group:isolated small bowel Crohn's disease group
A retrospective cohort study including individuals with active Crohn's disease (CD) who received 12-week induction therapy with upadacitinib (45 mg/day) was conducted.
control group:a non-small bowel Crohn's disease group
A retrospective cohort study including individuals with active Crohn's disease (CD) who received 12-week induction therapy with upadacitinib (45 mg/day) was conducted.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
the change in the International Bowel Ultrasound Segment Activity Score (IBUS-SAS)
大体时间:from baseline to week 12
The maximum value of IBUS-SAS (International Bowel Ultrasound Segment Activity Score) is 100. The theoretical minimum is 4, but the clinically effective minimum is 0. In general, the lower the score, the milder the intestinal inflammation.
from baseline to week 12

次要结果测量

结果测量
措施说明
大体时间
radiographic response
大体时间:at week 12
defined as a>25% or>2.0 mm reduction in bowel wall thickness [BWT] from baseline, or a>1.0 mm reduction in BWT from baseline accompanied by a decreased Color Doppler Signal grade
at week 12
change in clinical activity as measured by the Crohn's Disease Activity Index (CDAI)
大体时间:from baseline to week 12
The Crohn's Disease Activity Index (CDAI) has a theoretical maximum of 1100 and a theoretical minimum of 0. Consistent with the definition of disease activity in this scoring system, the lower the score, the lower the disease activity and the better the clinical status.
from baseline to week 12
changes in laboratory parameters (C-reactive protein)
大体时间:from baseline to week 12
from baseline to week 12
changes in laboratory parameters (Erythrocyte sedimentation rate)
大体时间:from baseline to week 12
from baseline to week 12

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2023年3月12日

初级完成 (实际的)

2024年10月12日

研究完成 (实际的)

2026年5月1日

研究注册日期

首次提交

2026年5月9日

首先提交符合 QC 标准的

2026年5月18日

首次发布 (实际的)

2026年5月19日

研究记录更新

最后更新发布 (实际的)

2026年5月19日

上次提交的符合 QC 标准的更新

2026年5月18日

最后验证

2026年5月1日

更多信息

与本研究相关的术语

其他研究编号

  • 2026ZSLYEC-305

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅